Validation study: a newly developed neuropathic pain Heat-Capsaicin-Warmth (HCW) sensitization model.

Validation study: a newly developed neuropathic pain Heat-Capsaicin-Warmth (HCW) sensitization model. - Gabapentin and remifentanil HCW pain study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34072

Enrollment

Registered

2010-06-03

Start date

2010-06-28

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nerve pain sensitivity to pain stimuli

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy male volunteers, age between 18 and 40 years, caucasian race, BMI between 18 and 27 kg/m2, non or moderate smoker (

Exclusion criteria

Exclusion criteria: Scar tissue on the anterior side of the dominant forearm, mental handicap, actual pain, history of serious allergies or allergic to gabapentin, remifentanil or capsaicin, regular/routine treatment with non-topical medications within 30 days prior to drug administration.

Design outcomes

Primary

Measure	Time frame
Pharmacodynamics: Size of the area of secondary hyperalgesia and tactile allodynia (von Frey and brush, respectively); VAS pain intensity sec and upon pinprick stimulation. Safety: Adverse events.	—

Secondary

Measure	Time frame
n.a.	—

Countries

Netherlands

Outcome results